Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents

Type 2 diabetes (T2D) is among the most common and costly disorders worldwide(1). The goal of current medical management of T2D is to transiently ameliorate hyperglycemia through daily dosing of one or more anti-diabetic drugs. Hypoglycemia and weight are common side effects of therapy, and sustaine...

Descripción completa

Detalles Bibliográficos
Autores principales: Scarlett, Jarrad M., Rojas, Jennifer M., Matsen, Miles E., Kaiyala, Karl J., Stefanovski, Darko, Bergman, Richard N., Nguyen, Hong T., Dorfman, Mauricio D., Lantier, Louise, Wasserman, David H., Mirzadeh, Zaman, Unterman, Terry G., Morton, Gregory J., Schwartz, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938755/
https://www.ncbi.nlm.nih.gov/pubmed/27213816
http://dx.doi.org/10.1038/nm.4101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938755/
https://www.ncbi.nlm.nih.gov/pubmed/27213816
http://dx.doi.org/10.1038/nm.4101

Ejemplares similares